ecancer
M

EHA 2022 on R-CODOX-M/R-IVAC vs. Dose-Adjusted EPOCH-R in Newly Diagnosed High-Risk Burkitt Lymphoma

By ecancer FEATURING Martine Chamuleau
By ecancer FEATURING Martine Chamuleau
0 views
June 21, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Recommended

AUTOPLAY
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
13:58
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Feat. M. Salamoon
14:03
SOHO Brazil 2023

2023 SOHO® Brazil: "Moving Beyond CODOX - How Disease Features …

Feat. J. Alderuccio
25:46
SOHO Highlights: State of the Art and Next Questions

SOHO Highlights - State of the Art & Next Questions: Aggressive …

Feat. L. Sehn
23:26
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Harnessing the Immune System in Patients With Lymphoma

Feat. S. Ansell
24:14
19th Annual International Ultmann Chicago Lymphoma Symposium

Prognostication and Treatment of Burkitt Lymphoma in the Modern Era

Feat. A. Olszewski
13:50
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021: Prognostication and Treatment of Burkitt Lymphoma in the …

Feat. A. Olszewski
10:00
2018 Pan Pacific Lymphoma Conference

The Tumor Microenvironment Using Immune Checkpoint Inhibitors

Feat. J. Gribben
33:55
ESO Lymphoma Course

Pathogenesis of Mature B-Cell Lymphomas: Germinal Center‐derived Lym…

Feat. A. Melnick